Table 16.

Descriptive reports of adverse outcomes

Author (sample size; treatment vs. control)	Results	Descriptive reports of adverse outcomes (results continued)
Fadeyev et al. [61] (33; 19 vs. 14)	Treatment group: 5 events; 26.3%	In the treatment group, 5/19 patients had various AEs during treatment (3 patients had more ventricular premature beats and 2 patients had an increased mean heart rate in conjunction with an increased number of ventricular premature beats). At the end of the follow-up period, one of the patients in the treatment group had an unstable episode of ventricular tachycardia. AEs in the control group were not reported.
Liu et al. [64] (136; 68 vs. 68)	Control group (0 events; 0.0%) vs. treatment group (9 events; 13.2%)	OR 21.87 (95% CI 1.25–383.87); p = 0.03 Absolute value (range), 0 fewer per 1000 (from 0 fewer to 0 fewer) Adverse reactions included mild insomnia, mild diarrhea, mild paroxysmal supraventricular tachycardia, and palpitations.
Nagasaki et al. [69] (95; 48 vs. 47)	Control group (0 events; 0.0%) vs. treatment group (0 events; 0.0%)	None of the patients experienced side effects such as arrhythmia, angina pectoris, or hypertension that would have required withdrawal or reduction of the dose of levothyroxine.
Stott et al. [73] (737; 368 vs. 369)	Control group (103 events, 27.9%) vs. treatment group (78 events, 21.2%)	HR of 0.94 (95% CI of 0.88–1.0); p = 0.053 Absolute value (range), 14 fewer per 1000 (from 0 fewer to 29 fewer) For serious AEs only
Zhao et al. [77] (369; 210 vs. 159)	Control group (13 events; 8.2%) vs. treatment group (16 events; 7.6%)	OR 0.93 (95% CI 0.43–1.99); p ≥ 0.05 Absolute value (range), 5 fewer per 1000 (from 45 fewer to 69 more) Adverse symptoms included palpitations, chest tightness, dizziness, perspiration, low back pain, and hunched back. No participant attempted to visit a physician due to adverse effects.